The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
Research and Practice in Thrombosis and Haemostasis (RPTH) shared a post on LinkedIn about a recent article by Deepa Gautam, adding:
“Are all platelets the same?
Or are we missing critical biology hiding in plain sight?
We still rely on platelet count and MPV in both research and the clinic.
But this study shows that platelets are far from uniform and that heterogeneity systematically shifts across disease states.
Here’s what this paper delivers.
Using a 12-marker spectral flow cytometry panel pus high – dimensional clustering (PlateletProfiler), the authors map platelet states at single – cell resolution.
Platelets exist along an activation continuum, not just ‘resting vs activated’:
- Resting
- Primed
- Aggregatory
- Procoagulant
Disease reshapes platelet composition across models:
- Inflammation (LPS) – expansion of primed plus aggregatory platelets
- Jak2V617F (MPN) – increase in aggregatory plus procoagulant platelets
- Cancer – enrichment of procoagulant platelets
Key mechanistic signal, all models showed:
- Increased reticulated (young) platelets
- Upregulation of activation plus immune markers (e.g., PD-L1, CD154)
This suggests:
- Accelerated thrombopoiesis
- Functionally ‘pre-activated’ circulating platelets
- A link between platelet biology and immune modulation
Why this matters
We’ve been treating platelets as a homogeneous population.
This framework opens the door to:
- Subpopulation-specific biomarkers
- More precise antiplatelet strategies
- Better mechanistic links between platelets, inflammation, and cancer”
Title: Characterizing mouse platelet heterogeneity across diverse disease models using spectral flow cytometry and high-dimensional analysis
Authors: Deepa Gautam, Emily M. Clarke, Rebecca L. Zon, Margaret R. Smith-Oliver, Avinash Kumar 5, Megan E. Sullivan, Panagiotis Karagiannis, Harvey G. Roweth, Elisabeth Battinelli
Read the Full Article on RPTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy